Clinical Trial Update: Efficacy and Safety of SOF/VEL + RBV and SOF/VEL/VOX for 12 Weeks in HCV Subjects With GT3b and Compensated Cirrhosis [Phase 4]

View source ↗

Summary

Phase 4 trial updating efficacy and safety of SOF/VEL with or without RBV and SOF/VEL/VOX for 12 weeks in hepatitis C patients with GT3b and compensated cirrhos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cirrhosis
• Hepatitis C

Drugs mentioned

• SOF/VEL (Sofosbuvir/Velpatasvir)
• SOF/VEL + RBV
• SOF/VEL/VOX (sofosbuvir/velpatasvir/voxilaprevir)

Snippet

Sponsor: Peking University People's Hospital | Conditions: Hepatitis C, Cirrhosis | Phase 4 | Status: UNKNOWN